Status:
COMPLETED
Immune Damage and Vaccination in COPD Patients
Lead Sponsor:
Centre Hospitalier Intercommunal Creteil
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
40-65 years
Brief Summary
Better understanding of the specificities of the vaccine response in patients with COPD
Detailed Description
Chronic obstructive pulmonary disease (COPD) will become the third leading cause of death worldwide in 2020 (3.5 million patients, 16500 deaths in France). Its socio-economic cost is related to the ha...
Eligibility Criteria
Inclusion
- Acceptance to participate in the protocol
- Affiliated to a social security scheme
- Age between 40 and 65 years COPD patients
- Diagnosis of moderate to very severe COPD with FEV1 / FVC \<0.7 and FEV1 \<80% of predicted value, cumulative smoking greater than 10PA
- Indication reminder dTP pertussis when the last booster \<5 years Patients without COPD
- FEV / FVC\> 0.8
- Indication reminder dTP pertussis when the last booster \<5 years
- Indication and patient's wish for an influenza vaccination
Exclusion
- Refusal to participate in the study
- Progressive cancer and / or treated in the last 5 years, uncontrolled heart failure, connective tissue disease, inflammatory disease of the digestive tract during treatment.
- Exacerbation or any upper or lower respiratory infection in the previous month.
- Any cause of immunodepression, including long-term oral corticosteroids.
- Pregnant or lactating woman
Key Trial Info
Start Date :
October 9 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 3 2023
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT03804138
Start Date
October 9 2018
End Date
February 3 2023
Last Update
April 14 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
CHI Créteil
Créteil, France, 94000
2
CHU Henri-Mondor
Créteil, France, 94000